EGFR and non-small cell lung carcinoma: However, Lyu et al. found that 2 years of treatment with icotinib resulted in a significantly lower risk of recurrence compared to 1 year of treatment in EGFR-mutant patients with stage II–IIIA NSCLC after R0 resection [30].